Oxurion Competitors and Similar CompaniesClear all
Oxurion's competitors and similar companies include Alnylam.
 Oxurion Oxurion (formerly known as ThromboGenics) is a biopharmaceutical company developing treatments to preserve vision in patients with diseases affecting the back of the eye. |  Alnylam Alnylam is a biopharmaceutical company that develops ribonucleic acid interference (RNAi) therapeutics for hepatic porphyria, primary hyperoxaluria type 1 (PH1), cardiovascular, and polyneuropathy treatments. | |
Founding Date | Founding Date 1991 | Founding Date 2002 |
Type | Type Public | Type Public |
Tags | ||
Locations | Locations Leuven, BE HQ Dublin 8, IE | |
Employees | Employees 785% increase | Employees 1,32324% increase |
Valuation ($) | Valuation ($) 626.1 k | Valuation ($) 36.5 b |
Financial | ||
Revenue (est.) | Revenue (est.) €555k (FY, 2025) | Revenue (est.) $3.7b (FY, 2025) |
Cost of goods | Cost of goods N/A | Cost of goods $677.2m (FY, 2025) |
Gross profit | Gross profit €937k (FY, 2025) | Gross profit $3b (FY, 2025) |
Net income | Net income (€3.7m) (FY, 2025) | Net income $313.7m (FY, 2025) |
Funding | ||
Total funding raised | Total funding raised $ 3.9m | Total funding raised $ 1.5b |
For sources of this data, please see the company profile
View Company Profiles
Alnylam
HQ
Cambridge, US
Employees
1,323↑ 24% increase
Alnylam is a biopharmaceutical company that develops ribonucleic acid interference (RNAi) therapeutics for hepatic porphyria, primary hyperoxaluria type 1 (PH1), cardiovascular, and polyneuropathy treatments.
View company